Business
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive preliminary data from two ongoing clinical trials evaluating the company's combination respiratory PreF vaccine candidates (RSV+hMPV±PIV3) leveraging its validated Trimer-Tag platform technology including:
About this update from Clover Biopharmaceuticals Ltd.
[{"type":"text","content":"-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection --","length":214,"tagName":"p","attribs":{}},{"type":"text","content":"-- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fold for hMPV and 4 fold for PIV3 (≥10 fold increases in PIV3 PreF-specific antibodies) were observed --","length":183,"tagName":"p","attribs":{}},{"type":"text","content":"-- Interim analysis from RSV re-vaccination trial demonstrates ≥60% higher trend in RSV neutralizing antibodies for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) in older adults previously receiving an initial dose of AREXVY --","length":248,"tagName":"p","attribs":{}},{"type":"text","content":"-- Potential first-in-class RSV+hMPV±PIV3 combination vaccine candidates to advance to Phase II clinical trials in the first half of 2026 --","length":140,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive preliminary data from two ongoing clinical trials evaluating the company's combination respiratory PreF vaccine candidates (RSV+hMPV±PIV3) leveraging its validated Trimer-Tag platform technology including:","length":490,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"A Phase I trial in Australia evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) combination vaccines compared head-to-head with SCB-1019 (RSV) in RSV vaccine-naïve older adults; and,","length":191,"tagName":"p"}]},{"val":[{"type":"text","content":"A Phase I trial in the U.S. evaluating re-vaccination with SCB-1019 compared head-to-head versus AREXVY (GSK's RSV vaccine) in older adults previously receiving AREXVY at least 2 seasons prior to enrolling.","length":210,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":401,"olType":false},{"type":"text","content":""We are pleased to announce positive Phase I clinical data indicating a potential best-in-class profile for our RSV+hMPV±PIV3 combinatio...